Em recrutamento
FASE
Número Europeu 2025-521712-19-00
M24-560 AndroMETa-CRC-56
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer (AndroMETa-CRC)
Detalhes
Destaques